Polymyalgia Rheumatica Market Report 2025

The polymyalgia rheumatica market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historical period can be attributed to factors such as increasing awareness among healthcare practitioners, the rising use of corticosteroids, the growth of specialty clinics, the introduction of biologic therapies, and increased healthcare budgets.

The polymyalgia rheumatica market size is expected to see strong growth in the next few years. It will grow to $1.73 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period is expected to be driven by the growing adoption of biologics, the expansion of precision medicine, accelerated drug approvals, broader reimbursements, and the expansion of clinical trials. Key trends for the forecast period include the development of combination therapies, advancements in personalized medicine, the growth of precision medicine, the integration of electronic health records, and improvements in biomarkers.

The increasing demand for personalized medicine is expected to drive the growth of the polymyalgia rheumatica market in the future. Personalized medicine involves medical treatments customized to an individual's genetic profile, lifestyle, and specific health conditions, leading to more effective outcomes. The demand for this approach is fueled by advancements in genetic research, growing patient expectations for tailored treatments, and improvements in diagnostic technologies. Through genetic research, a better understanding of genetic variations has allowed for treatments that target specific genetic markers. Personalized medicine helps identify the most effective drugs based on a patient's characteristics, leading to safer and more efficient treatment plans. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. This growth in personalized medicine is driving the expansion of the polymyalgia rheumatica market.

The growth of telemedicine services is also expected to contribute to the growth of the polymyalgia rheumatica market. Telemedicine leverages digital communication technologies such as video calls, phone calls, and online messaging to offer remote medical consultations, diagnoses, treatments, and follow-up care, eliminating the need for in-person visits. The rise in telemedicine is driven by increasing demand for convenient healthcare options and cost-effective solutions. Patients, particularly for non-urgent consultations, are seeking more convenient alternatives that telemedicine offers. These services help manage polymyalgia rheumatica (PMR) by enabling remote monitoring of symptoms, medication management, and regular follow-ups, all essential for controlling chronic pain and inflammation. For instance, according to the Australian Bureau of Statistics, in 2022-23, 87.7% of people used telehealth consultations, and this figure rose to 89.2% in 2023-24. Thus, the growth of telemedicine is fueling the expansion of the polymyalgia rheumatica market.

Major companies are focusing on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more targeted and effective treatment options. IL-6 receptor blockers are biological drugs that target IL-6, a pro-inflammatory cytokine involved in autoimmune diseases. By blocking IL-6, these drugs help reduce inflammation and alleviate symptoms, thus improving the quality of life for PMR patients. For instance, in February 2023, Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, announced that the FDA approved Kevzara (sarilumab) for treating polymyalgia rheumatica in adults who have not responded to corticosteroids or cannot tolerate tapering off them. Kevzara is the first and only biologic approved for this condition, and it works by inhibiting IL-6 signaling. In a study, 28.3% of patients treated with sarilumab achieved sustained remission after 52 weeks, compared to 10.3% of those on a placebo. Kevzara is administered via subcutaneous injection every two weeks and is also approved for moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is currently trading at $54.13 on NASDAQ.

Major players in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital.

Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in polymyalgia rheumatica report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the polymyalgia rheumatica market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Polymyalgia rheumatica (PMR) is an inflammatory condition that primarily affects older adults, leading to muscle pain and stiffness, especially in the shoulders, hips, and neck. It is characterized by aching and swelling in the muscles around the shoulders and hips, making it difficult to move and perform daily activities.

The primary treatment types for polymyalgia rheumatica include corticosteroids, nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and biologics. Corticosteroids are the most common treatment for PMR, helping to reduce inflammation and relieve symptoms by mimicking adrenal hormones. These medications can be administered orally, intravenously, or subcutaneously, and they are used for various patient types, including adults, geriatrics, and pediatrics. Distribution occurs through different channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The polymyalgia rheumatica market research report is one of a series of new reports that provides polymyalgia rheumatica market statistics, including the polymyalgia rheumatica industry global market size, regional shares, competitors with the polymyalgia rheumatica market share, detailed polymyalgia rheumatica market segments, market trends, and opportunities, and any further data you may need to thrive in the polymyalgia rheumatica industry. This polymyalgia rheumatica market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The polymyalgia rheumatica market consists of revenues earned by entities by providing services such as medication management, pain management, laboratory testing, and nutritional counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The polymyalgia rheumatica market includes sales of disease-modifying anti-rheumatic drugs, calcium and vitamin D supplements, assistive devices, and physical therapy aids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.